Voyager Therapeutics has unveiled a new program focused on Alzheimer’s disease (AD) that utilizes a proprietary IV-delivered TRACER™ capsid to target the APOE gene, specifically aiming to reduce the ...
- New program combines IV-delivered TRACER™ capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 variant while delivering the protective APOE2 variant - - Voyager’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results